Mikaël Croyal1, Stéphanie Billon-Crossouard1, Sophie Goulitquer1, Audrey Aguesse1, Luis León1, Fanta Fall1, Maud Chétiveaux1, Thomas Moyon1, Valentin Blanchard1, Khadija Ouguerram1, Gilles Lambert1, Estelle Nobécourt1, Michel Krempf2. 1. From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.). 2. From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.). michel.krempf@univ-nantes.fr.
Abstract
OBJECTIVE: ApoM (apolipoprotein M) binds primarily to high-density lipoprotein before to be exchanged with apoB (apolipoprotein B)-containing lipoproteins. Low-density lipoprotein (LDL) receptor-mediated clearance of apoB-containing particles could influence plasma apoM kinetics and decrease its antiatherogenic properties. In humans, we aimed to describe the interaction of apoM kinetics with other components of lipid metabolism to better define its potential benefit on atherosclerosis. APPROACH AND RESULTS: Fourteen male subjects received a primed infusion of 2H3-leucine for 14 hours, and analyses were performed by liquid chromatography-tandem mass spectrometry from the hourly plasma samples. Fractional catabolic rates and production rates within lipoproteins were calculated using compartmental models. ApoM was found not only in high-density lipoprotein (59%) and LDL (4%) but also in a non-lipoprotein-related compartment (37%). The apoM distribution was heterogeneous within LDL and non-lipoprotein-related compartments according to plasma triglycerides (r=0.86; P<0.001). The relationships between sphingosine-1-phosphate and apoM were confirmed in all compartments (r range, 0.55-0.89; P<0.05). ApoM fractional catabolic rates and production rates were 0.16±0.07 pool/d and 0.14±0.06 mg/kg per day in high-density lipoprotein and 0.56±0.10 pool/d and 0.03±0.01 mg/kg per day in LDL, respectively. Fractional catabolic rates of LDL-apoM and LDL-apoB100 were correlated (r=0.55; P=0.042). Significant correlations were found between triglycerides and production rates of LDL-apoM (r=0.73; P<0.004). CONCLUSIONS: In humans, LDL kinetics play a key role in apoM turnover. Plasma triglycerides act on both apoM and sphingosine-1-phosphate distributions between lipoproteins. These results confirmed that apoM could be bound to high-density lipoprotein after secretion and then quickly exchanged with a non-lipoprotein-related compartment and to LDL to be slowly catabolized.
OBJECTIVE:ApoM (apolipoprotein M) binds primarily to high-density lipoprotein before to be exchanged with apoB (apolipoprotein B)-containing lipoproteins. Low-density lipoprotein (LDL) receptor-mediated clearance of apoB-containing particles could influence plasma apoM kinetics and decrease its antiatherogenic properties. In humans, we aimed to describe the interaction of apoM kinetics with other components of lipid metabolism to better define its potential benefit on atherosclerosis. APPROACH AND RESULTS: Fourteen male subjects received a primed infusion of 2H3-leucine for 14 hours, and analyses were performed by liquid chromatography-tandem mass spectrometry from the hourly plasma samples. Fractional catabolic rates and production rates within lipoproteins were calculated using compartmental models. ApoM was found not only in high-density lipoprotein (59%) and LDL (4%) but also in a non-lipoprotein-related compartment (37%). The apoM distribution was heterogeneous within LDL and non-lipoprotein-related compartments according to plasma triglycerides (r=0.86; P<0.001). The relationships between sphingosine-1-phosphate and apoM were confirmed in all compartments (r range, 0.55-0.89; P<0.05). ApoM fractional catabolic rates and production rates were 0.16±0.07 pool/d and 0.14±0.06 mg/kg per day in high-density lipoprotein and 0.56±0.10 pool/d and 0.03±0.01 mg/kg per day in LDL, respectively. Fractional catabolic rates of LDL-apoM and LDL-apoB100 were correlated (r=0.55; P=0.042). Significant correlations were found between triglycerides and production rates of LDL-apoM (r=0.73; P<0.004). CONCLUSIONS: In humans, LDL kinetics play a key role in apoM turnover. Plasma triglycerides act on both apoM and sphingosine-1-phosphate distributions between lipoproteins. These results confirmed that apoM could be bound to high-density lipoprotein after secretion and then quickly exchanged with a non-lipoprotein-related compartment and to LDL to be slowly catabolized.
Authors: Julio A Chirinos; Lei Zhao; Yi Jia; Cecilia Frej; Luigi Adamo; Douglas Mann; Swapnil V Shewale; John S Millar; Daniel J Rader; Benjamin French; Jeff Brandimarto; Kenneth B Margulies; John S Parks; Zhaoqing Wang; Dietmar A Seiffert; James Fang; Nancy Sweitzer; Christina Chistoffersen; Björn Dahlbäck; Bruce D Car; David A Gordon; Thomas P Cappola; Ali Javaheri Journal: Circulation Date: 2020-04-02 Impact factor: 29.690
Authors: Shuang Yao; Jun Zhang; Yuxia Zhan; Yuanping Shi; Yang Yu; Lu Zheng; Ning Xu; Guanghua Luo Journal: Endocr Metab Immune Disord Drug Targets Date: 2020 Impact factor: 2.895